Page last updated: 2024-12-07
benzoylmetronidazole
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
metronidazole benzoate : A benzoate ester resulting from the formal condensation of benzoic acid with the hydroxy group of metronidazole. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 83213 |
| CHEMBL ID | 1466172 |
| CHEBI ID | 50688 |
| SCHEMBL ID | 366213 |
| MeSH ID | M0108393 |
Synonyms (66)
| Synonym |
|---|
| AC-14443 |
| HMS2569A06 |
| smr000217345 |
| benzoic acid 2-(2-methyl-5-nitro-imidazol-1-yl)-ethyl ester |
| MLS000590415 |
| NCGC00160502-01 |
| OPREA1_489419 |
| benzoylmetronidazole |
| flagyl s |
| 2-(2-methyl-5-nitro-1h-imidazol-1-yl)ethyl benzoate |
| 13182-89-3 |
| 2-methyl-5-nitro-1h-imidazole-1-ethyl benzoate |
| CHEBI:50688 , |
| metronidazole benzoate |
| D08214 |
| elyzol (tn) |
| metronidazole benzoate (usp) |
| 2-(2-methyl-5-nitroimidazol-1-yl)ethyl benzoate |
| 2-(2-methyl-5-nitro-imidazol-1-yl)ethyl benzoate |
| A806316 |
| benzoic acid 2-(2-methyl-5-nitro-1-imidazolyl)ethyl ester |
| a355c835xc , |
| metronidazole benzoate [usp:ban] |
| unii-a355c835xc |
| einecs 236-131-7 |
| benzoyl metronidazole |
| benzoylmetronildazole |
| FT-0628935 |
| AB06961 |
| AKOS015888108 |
| S5863 |
| CHEMBL1466172 |
| metronidazoli benzoas |
| metronidazole benzoate [ep monograph] |
| metronidazole benzoate [mart.] |
| metronidazole benzoate [usp monograph] |
| metronidazoli benzoas [who-ip latin] |
| klion suspension |
| metronidazole benzoate [usp-rs] |
| metronidazole benzoate [who-dd] |
| metronidazole benzoate [who-ip] |
| 5-nitro-2-methyl-1-(2-benzoyloxyethyl)-imidazole |
| SCHEMBL366213 |
| 2-(2-methyl-5-nitro-1-imidazolyl)ethyl benzoate |
| AC-33577 |
| 1h-imidazole-1-ethanol, 2-methyl-5-nitro-, 1-benzoate |
| benzoylmetronildazole; |
| DTXSID60157221 , |
| CCG-253836 |
| C90395 |
| CS-0090787 |
| HY-122975 |
| mfcd00693654 |
| AS-13537 |
| BCP28722 |
| metronidazole benzoate; 2-(2-methyl-5-nitro-1h-imidazol-1-yl)ethyl benzoate |
| Q12199321 |
| metronidazole benzoate;benzoyl metronidazole |
| AKOS040733724 |
| dtxcid0079712 |
| metronidazole benzoate (usp-rs) |
| metronidazole benzoate (usp:ban) |
| metronidazole benzoate (ep monograph) |
| metronidazole benzoate (mart.) |
| metronidazole benzoate (usp monograph) |
| solutitionkitsmetronidazole |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (5)
| Role | Description |
|---|---|
| antibacterial drug | A drug used to treat or prevent bacterial infections. |
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| antiparasitic agent | A substance used to treat or prevent parasitic infections. |
| antitrichomonal drug | A drug used to treat trichomonas infections. |
| prodrug | A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| benzoate ester | Esters of benzoic acid or substituted benzoic acids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 16.3601 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (16)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1515377 | Cytotoxicity against human A549 cells after 24 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2 | Metronidazole aryloxy, carboxy and azole derivatives: Synthesis, anti-tumor activity, QSAR, molecular docking and dynamics studies. |
| AID1515376 | Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2 | Metronidazole aryloxy, carboxy and azole derivatives: Synthesis, anti-tumor activity, QSAR, molecular docking and dynamics studies. |
| AID1515378 | Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2 | Metronidazole aryloxy, carboxy and azole derivatives: Synthesis, anti-tumor activity, QSAR, molecular docking and dynamics studies. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (35.71) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 50.55
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (50.55) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||